Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
AGAE Technologies is a private U.S.-based specialty chemical and biotech company focused on the large-scale manufacture and supply of rhamnolipid biosurfactants. The company commercializes high-purity mono- and di-rhamnolipid ingredients for research and industrial applications spanning personal care, cosmetics, pharmaceuticals, agriculture, bioremediation, home care, and enhanced oil recovery. Its core differentiation is a proprietary production platform covering strain, media, foam control, fermentation, downstream purification, and decolorization, which the company says enables cost-effective, scalable output. AGAE also markets rhamnolipid-based consumer products under the MayLu brand and has expanded manufacturing capacity through a full-scale plant complex in Asia. For a biotech analyst, AGAE is best understood as a commercial-stage industrial biotech and biosurfactant platform company rather than a therapeutics developer.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on AGAE Technologies.